Kaken Pharmaceutical Co., Ltd. (KKPCF)

Market Cap	954.12M -2.4%
Revenue (ttm)	542.37M -6.9%
Net Income	63.44M -17.3%
EPS	1.68 -16.5%
Shares Out	n/a
PE Ratio	15.04
Forward PE	n/a
Dividend	1.19 (4.59%)
Ex-Dividend Date	Sep 29, 2026

Volume	2
Open	26.00
Previous Close	26.00
Day's Range	22.30 - 26.00
52-Week Range	22.30 - 28.96
Beta	0.13
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 9, 2026

About Kaken Pharmaceutical

Kaken Pharmaceutical Co., Ltd. produces, markets, and sells medical products, medical devices, and agrochemicals in Japan and internationally. The company offers pharmaceutical products and medical devices, such as Clenafin, a topical treatment for onychomycosis; Artz, an anti-osteoarthritis agent; Fiblast, a wound-healing agent; Ecclock for the treatment of primary axillary hyperhidrosis; Regroth, a periodontal regenerative agent; Hernicore for the treatment of lumbar disc herniation; and Seprafilm, an adhesion barrier used primarily in surger...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1917
• Employees: 1,114
• Stock Exchange: OTCMKTS
• Ticker Symbol: KKPCF

Financial Performance

In fiscal year 2026, Kaken Pharmaceutical's revenue was 76.87 billion, a decrease of -18.25% compared to the previous year's 94.04 billion. Earnings were 2.14 billion, a decrease of -84.63%.

Financial numbers in JPY

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 25, 2026

Data Sources Report a data error